A 38-year-old male veteran with posttraumatic stress disorder has been taking prazosin for combat-related nightmares, titrated over six weeks to 10 mg at bedtime. At baseline, he reported nightly trauma-related nightmares with an average of five awakenings per night, a Pittsburgh Sleep Quality Index (PSQI) global score of 16, and a PCL-5 score of 62. At his current evaluation, the PSQI has improved to 11, and his PCL-5 has decreased to 51. He reports nightmares have decreased to approximately two per week, sleep onset latency has improved, and he feels somewhat more rested. However, he reports morning dizziness requiring him to sit on the bed for several minutes before standing, and his standing blood pressure is 98/62 mmHg with a resting supine blood pressure of 122/78 mmHg. He denies syncope or falls. The PMHNP is evaluating the treatment response and tolerability. Which of the following best represents the appropriate evaluation?